+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Healthcare Nanotechnology (Nanomedicine) - Global Market Trajectory & Analytics

  • ID: 5030234
  • Report
  • April 2021
  • Region: Global
  • 190 pages
  • Global Industry Analysts, Inc
Global Healthcare Nanotechnology (Nanomedicine) Market to Reach $475.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Healthcare Nanotechnology (Nanomedicine) estimated at US$183.9 Billion in the year 2020, is projected to reach a revised size of US$475.2 Billion by 2027, growing at a CAGR of 14.5% over the analysis period 2020-2027. Therapeutics, one of the segments analyzed in the report, is projected to record a 14.1% CAGR and reach US$369.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Regenerative medicine segment is readjusted to a revised 15.7% CAGR for the next 7-year period.



The U.S. Market is Estimated at $54.3 Billion, While China is Forecast to Grow at 14% CAGR

The Healthcare Nanotechnology (Nanomedicine) market in the U.S. is estimated at US$54.3 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$82.8 Billion by the year 2027 trailing a CAGR of 14% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.8% and 12.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.7% CAGR.

In-vitro diagnostics Segment to Record 16.3% CAGR

In the global In-vitro diagnostics segment, USA, Canada, Japan, China and Europe will drive the 16.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$5.7 Billion in the year 2020 will reach a projected size of US$16.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$56.9 Billion by the year 2027.

Select Competitors (Total 46 Featured):
  • Abbott Laboratories
  • Celgene Corporation
  • CombiMatrix Corporation
  • GE Healthcare
  • Johnson & Johnson
  • Leadiant Biosciences, Inc.
  • Mallinckrodt PLC
  • Merck & Co., Inc.
  • NanoSphere Health Sciences, Inc.
  • Pfizer, Inc.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Healthcare Nanotechnology (Nanomedicine) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Regenerative Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Regenerative Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Regenerative Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for In-vitro Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for In-vitro Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for In-vitro Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for In-vivo Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for In-vivo Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for In-vivo Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 16: World Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 17: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 18: World 15-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 19: World Current & Future Analysis for Anticancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 20: World Historic Review for Anticancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 21: World 15-Year Perspective for Anticancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 22: World Current & Future Analysis for CNS Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 23: World Historic Review for CNS Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 24: World 15-Year Perspective for CNS Product by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 25: World Current & Future Analysis for Anti-infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 26: World Historic Review for Anti-infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 27: World 15-Year Perspective for Anti-infective by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 28: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 29: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 30: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • Table 31: USA Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 32: USA Historic Review for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 33: USA 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Percentage Breakdown of Value Sales for Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines for the Years 2012, 2020 & 2027
  • Table 34: USA Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 35: USA Historic Review for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 36: USA 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Application - Percentage Breakdown of Value Sales for Anticancer, CNS Product, Anti-infective and Other Applications for the Years 2012, 2020 & 2027
  • Table 37: Canada Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: Canada Historic Review for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 39: Canada 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Percentage Breakdown of Value Sales for Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines for the Years 2012, 2020 & 2027
  • Table 40: Canada Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 41: Canada Historic Review for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 42: Canada 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Application - Percentage Breakdown of Value Sales for Anticancer, CNS Product, Anti-infective and Other Applications for the Years 2012, 2020 & 2027
  • Table 43: Japan Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: Japan Historic Review for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 45: Japan 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Percentage Breakdown of Value Sales for Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines for the Years 2012, 2020 & 2027
  • Table 46: Japan Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 47: Japan Historic Review for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 48: Japan 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Application - Percentage Breakdown of Value Sales for Anticancer, CNS Product, Anti-infective and Other Applications for the Years 2012, 2020 & 2027
  • Table 49: China Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: China Historic Review for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 51: China 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Percentage Breakdown of Value Sales for Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines for the Years 2012, 2020 & 2027
  • Table 52: China Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 53: China Historic Review for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 54: China 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Application - Percentage Breakdown of Value Sales for Anticancer, CNS Product, Anti-infective and Other Applications for the Years 2012, 2020 & 2027
  • Table 55: Europe Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 56: Europe Historic Review for Healthcare Nanotechnology (Nanomedicine) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 57: Europe 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 58: Europe Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 59: Europe Historic Review for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 60: Europe 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Percentage Breakdown of Value Sales for Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines for the Years 2012, 2020 & 2027
  • Table 61: Europe Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 62: Europe Historic Review for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 63: Europe 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Application - Percentage Breakdown of Value Sales for Anticancer, CNS Product, Anti-infective and Other Applications for the Years 2012, 2020 & 2027
  • Table 64: France Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 65: France Historic Review for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 66: France 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Percentage Breakdown of Value Sales for Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines for the Years 2012, 2020 & 2027
  • Table 67: France Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 68: France Historic Review for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 69: France 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Application - Percentage Breakdown of Value Sales for Anticancer, CNS Product, Anti-infective and Other Applications for the Years 2012, 2020 & 2027
  • Table 70: Germany Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 71: Germany Historic Review for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 72: Germany 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Percentage Breakdown of Value Sales for Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines for the Years 2012, 2020 & 2027
  • Table 73: Germany Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 74: Germany Historic Review for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 75: Germany 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Application - Percentage Breakdown of Value Sales for Anticancer, CNS Product, Anti-infective and Other Applications for the Years 2012, 2020 & 2027
  • Table 76: Italy Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 77: Italy Historic Review for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 78: Italy 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Percentage Breakdown of Value Sales for Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines for the Years 2012, 2020 & 2027
  • Table 79: Italy Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 80: Italy Historic Review for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 81: Italy 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Application - Percentage Breakdown of Value Sales for Anticancer, CNS Product, Anti-infective and Other Applications for the Years 2012, 2020 & 2027
  • Table 82: UK Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 83: UK Historic Review for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 84: UK 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Percentage Breakdown of Value Sales for Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines for the Years 2012, 2020 & 2027
  • Table 85: UK Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 86: UK Historic Review for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 87: UK 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Application - Percentage Breakdown of Value Sales for Anticancer, CNS Product, Anti-infective and Other Applications for the Years 2012, 2020 & 2027
  • Table 88: Rest of Europe Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 89: Rest of Europe Historic Review for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 90: Rest of Europe 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Percentage Breakdown of Value Sales for Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines for the Years 2012, 2020 & 2027
  • Table 91: Rest of Europe Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 92: Rest of Europe Historic Review for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 93: Rest of Europe 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Application - Percentage Breakdown of Value Sales for Anticancer, CNS Product, Anti-infective and Other Applications for the Years 2012, 2020 & 2027
  • Table 94: Asia-Pacific Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 95: Asia-Pacific Historic Review for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 96: Asia-Pacific 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Percentage Breakdown of Value Sales for Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines for the Years 2012, 2020 & 2027
  • Table 97: Asia-Pacific Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 98: Asia-Pacific Historic Review for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 99: Asia-Pacific 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Application - Percentage Breakdown of Value Sales for Anticancer, CNS Product, Anti-infective and Other Applications for the Years 2012, 2020 & 2027
  • Table 100: Rest of World Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 101: Rest of World Historic Review for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 102: Rest of World 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Product Segment - Percentage Breakdown of Value Sales for Therapeutics, Regenerative Medicine, In-vitro Diagnostics, In-vivo Diagnostics and Vaccines for the Years 2012, 2020 & 2027
  • Table 103: Rest of World Current & Future Analysis for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 104: Rest of World Historic Review for Healthcare Nanotechnology (Nanomedicine) by Application - Anticancer, CNS Product, Anti-infective and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 105: Rest of World 15-Year Perspective for Healthcare Nanotechnology (Nanomedicine) by Application - Percentage Breakdown of Value Sales for Anticancer, CNS Product, Anti-infective and Other Applications for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 46
Note: Product cover images may vary from those shown
Adroll
adroll